Skip to main content

Find Clinical Trials

Home
Conditions
Adenocarcinoma

Clinical trial condition

Adenocarcinoma

Explore clinical trials studying Adenocarcinoma. Study availability and eligibility vary by location and protocol.

5,072 public trials 1,188 recruiting studies

Refine in advanced search Browse all conditions

Adenocarcinoma trial results

Not yet recruiting

Denosumab Strategy for Liver Cancer With Bone Metastases

NCT07537972

Conditions: Adenocarcinoma, Bone Metastases, Carcinoma, +10 more
Locations: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China

View Trial Details

Not yet recruiting

HISMAR: Intraoperative Margin Assessment Using the Histolog® Scanner to Reduce Reoperation in Breast-Conserving Surgery

NCT07527468

Conditions: Adenocarcinoma, Breast Cancer, Breast Carcinoma In Situ, +19 more
Locations: Centre Hospitalier du Valais Romand (CHVR) Sion, Valais, Switzerland

View Trial Details

Not yet recruiting

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

NCT07522411

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Not specified

View Trial Details

Not yet recruiting

A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma

NCT07522476

Conditions: Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +4 more
Locations: The First Affiliated Hospital，Zhejiang University School of Medicine Hangzhou, Zhejiang, China

View Trial Details

Not yet recruiting

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

NCT07518706

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Not specified

View Trial Details

Not yet recruiting

The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma

NCT07514533

Conditions: Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +3 more
Locations: Not specified

View Trial Details

Not yet recruiting

Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients

NCT07514455

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +14 more
Locations: Asan Medical Center Seoul, South Korea

View Trial Details

Not yet recruiting

A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

NCT07515469

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +11 more
Locations: Not specified

View Trial Details

Not yet recruiting

Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial

NCT07514429

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
Locations: Asan Medical Center Seoul, South Korea

View Trial Details

Not yet recruiting

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

NCT07511504

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
Locations: OHSU Knight Cancer Institute Portland, Oregon, United States

View Trial Details